Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

Mostrar otras versiones (1)

CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B cell leukemia and lymphoma. Many researchers are now trying to develop CAR T cells for various types of cancer. For multiple myeloma (MM), B-cell maturation antigen (BCMA) has been recently proved to be a promis...

Descripción completa

Detalles Bibliográficos
Autor principal: Hosen, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966463/
https://www.ncbi.nlm.nih.gov/pubmed/31847470
http://dx.doi.org/10.3390/cancers11122024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966463/
https://www.ncbi.nlm.nih.gov/pubmed/31847470
http://dx.doi.org/10.3390/cancers11122024

Ejemplares similares